Multivalent entrain-and-amplify immunotherapeutics for carcinoma
US8084592B2 · kind B2 · utility
8Cited by
17References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2006 |
| Grant date | Dec 27, 2011 |
| Priority date | — |
| Expiry date | Mar 25, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/545
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.